EnteroMedics Inc. (ETRM)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.19+0.00 (+0.11%)
At close: 4:00 PM EDT

0.18 -0.01 (-4.66%)
After hours: 7:59 PM EDT

People also watch:
CPRXAEZSBIODAPPYIMUC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.20
Prev Close0.19
Bid0.18 x 1000
Ask0.20 x 2000
Day's Range0.19 - 0.20
52wk Range0.16 - 5.85
1y Target EstN/A
Market Cap5.16M
P/E Ratio (ttm)-0.05
Beta2.41
Volume8,326,072
Avg Vol (3m)2,741,739
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    EnteroMedics Announces Appointment of Gary Blackford to its Board of Directors

    ST. PAUL, Minn., Aug. 17, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, today announced the appointment of Gary Blackford to its Board of Directors, effective August 16, 2016. The Company also announced that Anthony Jansz will step down from the Board effective August 16, 2016. "On behalf of the Board of Directors, I would like to thank Mr. Jansz for his contribution and service to the company.

  • PR Newswire11 days ago

    EnteroMedics Announces Publication of 24 Month ReCharge Clinical Study Data in Obesity Surgery

    ST. PAUL, Minn., Aug. 15, 2016 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of 24 month results from the Company's ReCharge Clinical Study.  The article, titled "Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial," was published in Obesity Surgery (DOI: 10.1007/s11695-016-2325-7), and is available online here. "The ability to sustain meaningful weight loss is vital when considering a viable long term solution for treating obesity and its related comorbidities," said Caroline M. Apovian, MD, FACP, FACN, Director, Nutrition and Weight Management, Professor of Medicine at Boston University School of Medicine, and lead author of the article.

  • EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
    Capital Cube14 days ago

    EnteroMedics, Inc. :ETRM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

    Categories: Yahoo Finance Click here to see latest analysis EnteroMedics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of EnteroMedics, Inc. – LivaNova Plc, Boston Scientific Corporation, NeuroMetrix, Inc., St. Jude Medical, Inc., Abbott Laboratories, Johnson & Johnson and Natus Medical Incorporated (LIVN-US, BSX-US, NURO-US, STJ-US, ... Read more (Read more...)